Survival-inferred fragility index of FDA-approved cancer drugs using surrogate endpoints

被引：0
|
作者：
Ofer, Jonathan
Gilboa, Shai
Pras, Yarden
Markel, Gal
Bomze, David
Meirson, Tomer
机构：
[1] Beilinson Med Ctr, Davidoff Canc Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1573
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Informative censoring of surrogate end-point data in FDA-approved cancer drugs
    Meirson, T.
    Ofer, J.
    Markel, G.
    Pras, Y.
    Gilboa, S.
    ANNALS OF ONCOLOGY, 2023, 34 : S924 - S924
  • [2] Quality of Life, Overall Survival, and Costs of Cancer Drugs Approved Based on Surrogate Endpoints
    Rupp, Tracy
    Zuckerman, Diana
    JAMA INTERNAL MEDICINE, 2017, 177 (02) : 276 - 277
  • [3] Repurposing of FDA-approved drugs against cancer - focus on metastasis
    Ozsvari, Bela
    Lamb, Rebecca
    Lisanti, Michael P.
    AGING-US, 2016, 8 (04): : 567 - 568
  • [4] Mechanisms of action for FDA-approved drugs targeting breast cancer
    Dhilna, Francis
    Binitha, R. N.
    Riswina, Nissar
    Divya, Sebatain
    Rima, Joseph
    Janish, P. A.
    Subin, Balachandran
    REVISTA DE SENOLOGIA Y PATOLOGIA MAMARIA, 2025, 38 (01):
  • [5] Survival-Inferred Fragility Index of Phase 3 Clinical Trials Evaluating Immune Checkpoint Inhibitors
    Bomze, David
    Asher, Nethanel
    Ali, Omar Hasan
    Flatz, Lukas
    Azoulay, Daniel
    Markel, Gal
    Meirson, Tomer
    JAMA NETWORK OPEN, 2020, 3 (10)
  • [6] Targeting nutrient metabolism with FDA-approved drugs for cancer chemoprevention: Drugs and mechanisms
    Xie, Yifei
    Yao, Ke
    Dong, Zigang
    Liu, Kangdong
    CANCER LETTERS, 2021, 510 : 1 - 12
  • [7] Unveiling FDA-Approved Drugs and Formulations in the Management of Bladder Cancer: A Review
    Bansal, Keshav
    Chaudhary, Neeraj
    Bhati, Hemant
    Vanshita
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2025, 26 (01) : 48 - 62
  • [8] COST-EFFECTIVENESS OF FDA-APPROVED CANCER DRUGS SINCE 2000
    Winn, A.
    Neumann, P. J.
    VALUE IN HEALTH, 2013, 16 (03) : A141 - A141
  • [9] Many FDA-approved cancer drugs might lack clinical benefit
    Das, Manjulika
    LANCET ONCOLOGY, 2018, 19 (02): : E82 - E82
  • [10] Repurposing of FDA-approved drugs as novel radiosensitisers in hypoxic prostate cancer
    Bibby, B.
    Thiruthaneeswaran, N.
    Yang, L.
    McArt, D.
    O'Reilly, P.
    Roberts, D.
    Choudhury, A.
    West, C.
    RADIOTHERAPY AND ONCOLOGY, 2018, 127 : S195 - S195
12345